Scientists probe why some melanoma patients respond to immunotherapy
NCT ID NCT02626065
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 32 people with advanced melanoma who were treated with the immunotherapy drug Nivolumab. Researchers took blood samples before and during treatment to track changes in immune cells. The goal was to find differences between patients whose tumors shrank or stayed stable and those whose cancer kept growing, which could lead to better treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nivolumab
- What this could lead to
- If successful, this could help doctors predict which melanoma patients will benefit from Nivolumab and improve treatment strategies.
- What could go wrong
- This is a small, completed study focused on understanding immune responses, not testing a new treatment. Results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma